C4C1F171-9B72-4527-9C03-39C2C00A5B6C
—
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- —
- cancer_type_detailed
- —
- subtype
- —
- overall_survival_months
- 24.24441524310118
- age_years
- 62
- sex
- Male
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- E2F_TARGETS+0.706
- G2M_CHECKPOINT+0.661
- MYC_TARGETS_V2+0.608
- MYC_TARGETS_V1+0.589
- DNA_REPAIR+0.506
- MITOTIC_SPINDLE+0.505
- INTERFERON_ALPHA_RESPONSE+0.472
- UNFOLDED_PROTEIN_RESPONSE+0.448
- WNT_BETA_CATENIN_SIGNALING+0.388
- NOTCH_SIGNALING+0.359
Top 10 suppressed
- KRAS_SIGNALING_DN-0.424
- PANCREAS_BETA_CELLS-0.360
- HEDGEHOG_SIGNALING-0.355
- BILE_ACID_METABOLISM-0.312
- MYOGENESIS-0.296
- COAGULATION-0.259
- XENOBIOTIC_METABOLISM-0.201
- INFLAMMATORY_RESPONSE-0.186
- KRAS_SIGNALING_UP-0.179
- REACTIVE_OXYGEN_SPECIES_PATHWAY-0.161
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
10 twins match this tumor's tissue · 0 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | 592CC5DC-4DB7-4961-AB2B-89C8FE4A83D3 | — | — | 0.923 |
| 2 | 50DE1FDE-B85E-4677-B0F8-08275DA41A6E | — | — | 0.914 |
| 3 | 98D004A9-E3F0-448E-BFE2-359F25DF356C | — | — | 0.909 |
| 4 | SRR934964 | — | — | 0.905 |
| 5 | SRR934975 | — | — | 0.901 |
| 6 | 9970B75F-7AC6-431B-BDBB-120D01582CBE | — | — | 0.887 |
| 7 | 6A30D8D0-DDB8-4B34-8BCB-46986144F551 | — | — | 0.886 |
| 8 | D717EAB5-3C67-4EF0-99BF-3416278BE492 | — | — | 0.876 |
| 9 | E0DE33EA-C3DF-478E-9C4D-86E3C7B3A1D9 | — | — | 0.875 |
| 10 | SRR934748 | — | — | 0.874 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 29 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| E2F_TARGETS | 0.706 | Inavolisib | — uncovered |
| G2M_CHECKPOINT | 0.661 | Inavolisib | — uncovered |
| MYC_TARGETS_V2 | 0.608 | Idelalisib | — uncovered |
| MYC_TARGETS_V1 | 0.589 | Inavolisib | — uncovered |
| DNA_REPAIR | 0.506 | Idelalisib | — uncovered |
| MITOTIC_SPINDLE | 0.505 | Inavolisib | — uncovered |
| INTERFERON_ALPHA_RESPONSE | 0.472 | Inavolisib | — uncovered |
| UNFOLDED_PROTEIN_RESPONSE | 0.448 | Idelalisib | — uncovered |
| WNT_BETA_CATENIN_SIGNALING | 0.388 | Inavolisib | — uncovered |
| NOTCH_SIGNALING | 0.359 | Inavolisib | — uncovered |
| TGF_BETA_SIGNALING | 0.320 | Inavolisib | — uncovered |
| MTORC1_SIGNALING | 0.307 | Inavolisib | — uncovered |
| INTERFERON_GAMMA_RESPONSE | 0.292 | Idelalisib | — uncovered |
| ANGIOGENESIS | 0.272 | Remibrutinib | — uncovered |
| OXIDATIVE_PHOSPHORYLATION | 0.251 | Remibrutinib | — uncovered |
| PI3K_AKT_MTOR_SIGNALING | 0.251 | Inavolisib | — uncovered |
| PROTEIN_SECRETION | 0.171 | Remibrutinib | — uncovered |
| CHOLESTEROL_HOMEOSTASIS | 0.164 | Remibrutinib | — uncovered |
| ANDROGEN_RESPONSE | 0.155 | Inavolisib | — uncovered |
| APOPTOSIS | 0.145 | Idelalisib | — uncovered |